Mamolo C, Welch V, Walter RB, Cappelleri JC, Brockbank J, Cawson M, Knight C, Wilson M. Budget impact analysis of gemtuzumab ozogamicin for the treatment of CD33-positive acute myeloid leukemia. Pharmacoeconomics. 2021 Jan;39(1):121-31. doi: 10.1007/s40273-020-00976-6
Walter R, Mamolo C, Welch V, Brockbank J, Cawson M, Knight C, Wilson M. Budget-impact analysis for gemtuzumab ozogamicin in CD33+ acute Myeloid Leukemia. Poster presented at the XXXVII World Congress International Society of Hematology (ISH); September 14, 2018. Vancouver, Canada.